Research programme: eye disorder therapies - EyePoint Pharmaceuticals

Drug Profile

Research programme: eye disorder therapies - EyePoint Pharmaceuticals

Latest Information Update: 05 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Icon Bioscience
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Age-related macular degeneration; Diabetic macular oedema; Eye-Disorders; Glaucoma; Keratoplasty rejection; Uveitis

Most Recent Events

  • 28 Mar 2018 Icon Bioscience has been acquired by EyePoint Pharmaceuticals
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Intraocular, Controlled release)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in USA (Intraocular, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top